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Our objective was to determine the impact of telemedicine (TM) interventions on the management of type 1 diabetes (T1DM)
in youth. We performed a systematic review of randomized trials that evaluated TM interventions involving transmission of
blood glucose data followed by unsolicited scheduled clinician feedback. We found no apparent eﬀect of the TM interventions
on hemoglobin A1c (HbA1c), severe hypoglycemia, or diabetic ketoacidosis. The limited data available on patient satisfaction,
quality of life, and cost also suggested no diﬀerences between groups. It is unlikely that TM interventions, as performed in the
assessed studies, had a substantial eﬀect on glycemic control or acute complications. However, it remains possible that there are
other beneﬁts of TM not adequately reported, that newer TM strategies may be more eﬀective and that interventions may beneﬁt
subgroups of youth, such as those with the poor glycemic control, adolescents, or those living in remote areas.
1.Introduction
Intensiveglycemiccontroldelaysandpreventsmicrovascular
and macrovascular complications of type 1 diabetes (T1DM)
[1, 2]. Despite advances in insulin preparations and delivery
mechanisms for insulin, glycemic control for many pediatric
patients with T1DM remains suboptimal. An international
study comparing glycemic control among pediatric diabetes
centres failed to show a correlation with insulin regimen,
suggesting that other factors, such as the organization of
delivery of care and the number of staﬀ on the diabetes
team, may be critical to attaining optimal blood glucose
control [3].
The intensive treatment protocol used in the Diabetes
Control and Complications Trial (DCCT) included tele-
phone contacts to adjust insulin regimens daily for the
ﬁrst week and then weekly thereafter. The intervention also
involved an intensive insulin regimen, increased frequency
of clinic visits, and intensive blood glucose monitoring
[4]. Although shown to be eﬀective in improving glycemic
control, these intensive measures are not feasible to carry out
in routine practice.
Moreover, the particular challenges presented by youth
with T1DM necessitate innovative management strategies
[5]. One strategy for improving glycemic control is the
use of telemedicine (TM). We distinguish routine T1DM
management that may include solicited remote commu-
nication between patients and the diabetes team on an
as-needed basis from TM interventions as deﬁned in
our study. We deﬁne TM to be the scheduled remote
transmission of blood glucose (BG) data by means such
as telephone, fax, mobile phone, or internet with unso-
licited clinician feedback. This deﬁnition of TM is con-
sistent with that used previously by authors of systematic
reviews on this topic in the adult population with T1DM
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The impact of these types of interventions on the
management of youth with T1DM is unknown. A previous
systematic review that included studies published up to July
2004 in adults and youth with all types of diabetes [7]a n d
another that included studies up to June 2003 in adults
and youth with T1DM [6]b o t hr e p o r tn oe ﬀect of TM on
glycemic control. Since that time, new technologies such
as short message service (SMS) have become more widely
accessible to and utilized by youth.
Our objective is to assess the impact of TM interventions
on glycemic control in youth with T1DM. We report the
results of an updated systematic review that includes seven
new randomized trials, focuses only on the impact of TM
for T1DM in youth, and uses rigorous methodology. We also
identifyaneedtoobtainadditionaldataonpotentialbeneﬁts
of using telemedicine in clinical practice that extend beyond
its impact on glycemic control, including engaging and
empowering adolescents with novel technologies, improving
patient and family quality of life, and enhancing patient and
family education.
2. Methods
MEDLINE, EMBASE, CCTR, CINAHL (EBSCOHost), ISI
Web of Science, and clinicaltrials.gov were searched up to
December 21, 2009 without language restriction. Available
indexing terms and text words for T1DM, TM, or related
terms, and randomized controlled (RCT) or controlled
clinical trials (CCT) were used. The Telemedicine Infor-
mation Exchange (an international searchable database of
telemedicine citations), relevant conference abstracts from
2007-2008, and reference lists of included studies were also
searched.
Eligibility criteria for study inclusion were (1) youth less
than 19 years with T1DM; (2) TM interventions involving
scheduled routine transmission of blood glucose (BG) data
with unsolicited scheduled clinician feedback; (3) inclusion
of a control group that did not receive unsolicited feedback
about transmitted BG data; (4) RCT or CCT. Studies were
excluded if participants were pregnant or had non-T1DM.
Two reviewers independently assessed studies for eligibility
and validity and extracted data. Disagreements were resolved
through consultation with a third reviewer. Assessment of
study validity was done using the Cochrane Collaboration’s
tool for assessing risk of bias [8]. The Grades of Recommen-
dation, Assessment, Development, and Evaluation (GRADE)
system was used to assess the quality of the body of evidence.
The primary outcome assessed was HbA1c as a marker
of long-term complications of diabetes. Treatment eﬀect was
expressed as a mean diﬀerence with 95% CI for continuous
outcomes and as an odds ratio (OR) with 95% CI for
dichotomous outcomes. Meta-analyses using a random-
eﬀectsmodelwereperformedusingReviewManagerVersion
5.0 software. We used the I2 statistic to determine the pro-
portion of variation in study estimates due to heterogeneity.
Publication bias was assessed using funnel plots.
We hypothesized, ap r i o r i , that the following fac-
tors may explain heterogeneity (variability in participants,
interventions, outcomes, study design, and risk of bias
amongstudies):(1)age,(2)baselineHbA1c,(3)frequencyof
data transmission, and (4) timing of outcome measurement.
Insuﬃcientdataprohibitedwithin-studycomparisonstotest
these hypotheses; however, between-study comparisons were
performed.
3. Results
Of 434 studies identiﬁed, 377 were excluded after review of
titles and abstracts because they were duplicates or involved
the wrong population, intervention, and/or study design; 57
studies were retrieved in full text. Ten studies, involving 609
youth, met eligibility criteria [9–18] (see Figure 1 for details
of the process of the selection of studies for inclusion and
Table 1 for study characteristics). Data from nine of the
ten studies were included in the meta-analysis. Data from
one study [13] was excluded because the primary outcome,
HbA1c, was reported as a modeled HbA1c eﬀect and
therefore could not statistically be combined with outcomes
reported in the other studies. We report the results from this
study separately.
The shortest study lasted 3 months and the longest 12
months. Most studies were 6 months in duration. All studies
involved a minimum of every two-week frequency of data
transmission except one that had a school-based monthly
videoconference [13]. Clinic visits were held every three
months, except in one study [17] in which patients attended
clinic only every 6 months (Table 1). Most studies used
telephone, modem, or fax to transmit data. One [18] used
SMS,andoneusedvideoconference[13].Themeanageofall
participants ranged from 10 to 17 years. Most studies limited
inclusion criteria to participants with suboptimal glycemic
control. The mean baseline HbA1c in the studies included in
the meta-analysis ranged from 8.2% to 10.2% (Table 2).
For all outcomes, the quality of the body of evidence
was downgraded because of elements of study design and
execution (Table 3) and because the GRADE system to assess
quality of evidence necessitates a downgrade for the use
of any indirect measure, such as HbA1c as a marker for
long-term complications [8]. The evidence regarding severe
hypoglycemia and DKA was also downgraded because rare
event rates and wide conﬁdence intervals reﬂect uncertainty
about the estimate of eﬀect. Therefore, for glycemic control,
severe hypoglycaemia, and DKA, the quality evidence is
graded as low (Table 4).
There was no statistically signiﬁcant eﬀect of TM on
HbA1c (mean diﬀerence −0.12, 95% CI, −0.35 to 0.11) with
no contribution of statistical heterogeneity to the variability
in eﬀect estimate (I2 = 0%) (Figure 2(a)). Data from the
single study not included in the meta-analysis [13] showed
a signiﬁcant diﬀerence in slope of the modelled HbA1c eﬀect
between the TM and control groups during the ﬁrst six
months of the intervention (P<. 02), but none after the six
month point. The absolute decrease in the modelled HbA1c
in the TM group at six months was less than 0.5%.
Between-study comparisons based on age, baseline
HbA1c, frequency of data transmission, and timing ofInternational Journal of Pediatric Endocrinology 3
Table 1: Study characteristics of the 10 studies that met inclusion criteria.
Lead author, year (ref) Sample size
Frequency and mode of
data transmission and
feedback
Duration
(months) Cointerventions
Frequency of
clinic visits
(months)
Study design
Cadario, 2007 [9]2 8 2w e e k sv i am o d e m ,
clinician within 1 week 6N o n e 3R C T
Chase, 2000 [10]7 0 2w e e k sv i am o d e m ,
clinician by telephone 6N o n e
3 (TM group did
n o ta t t e n da t3
months)
RCT
Gay, 2006 [11] 100
2 weeks, printout of
glucometer data faxed,
pediatric endocrinologist
advice by mail or phone
within 5 days
6N o n e 3R C T
Howe, 2005 [12]7 5
TM plus ED: weekly phone
calls for 3 months, then
bimonthly for 3 months
with diabetes nurse
educator
6 Education session 3 RCT, 3-arms
Izquierdo, 2009 [13]4 1 Monthly videoconference
with immediate feedback 12 Education modules 3
RCT, ran-
domization
at the school
level
Lawson, 2005 [14]4 6
Weekly telephone contact
with diabetes nurse
educator
6N o n e 3
RCT, single-
blinded,
parallel
design
Marrero, 1995 [15] 106
2 weeks, data management
system reviewed by
clinician, feedback
frequency determined by
algorithms
12 None 3
RCT,
repeated
measures
design
Nunn, 2006 [16] 123 Bimonthly phone calls with
nurse educator 5−8
Educational program
by phone using
written material and
illustrations
3R C T
Panagiotopoulos, 2003
[17] 50 Phone contact with
educator 1-2 times weekly 6
Education provided
during calls and teen
issues addressed
6R C T
Rami, 2006 [18]3 6
Every BG checked or at
least daily via short
message service (SMS),
reviewed weekly by
diabetologist with SMS
feedback
3N o n e 3
Randomized
cross-over
trial
HbA1c measurement revealed no diﬀerences in pooled
estimates between subgroups. A post hoc between-study
comparison based on whether feedback was given in real-
time or if it was stored and forwarded also found no diﬀer-
ence in HbA1c at the end of the intervention. The pooled
estimateforabetween-studyanalysiscomparingstudieswith
mean baseline HbA1c values <9.0% to those with ≥9.0%
trended toward favoring TM in the subgroup of studies
with baseline HbA1c ≥9% (Figure 3). Publication bias was
unlikely based on visual examination of the funnel plot.
Five studies reported frequency of severe hypoglycaemia
and DKA [9, 10, 13, 14, 18]. The pooled estimates revealed
no eﬀect on severe hypoglycemia (OR 1.42, 95% CI, 0.22 to
9.32) or DKA (OR 1.02, 95% CI, 0.24 to 4.23) (Figures 2(b)
and2(c)).Asensitivityanalysisincludingdatafromthestudy
not included in the meta-analysis [13] did not signiﬁcantly
change the pooled estimate for severe hypoglycemia or DKA.
However, the school-based study did ﬁnd a decrease
in urgent visits to the school nurses for diabetes-related
problems and urgent calls to the diabetes center in the TM
g r o u pc o m p a r e dt oc o n t r o l[ 13]. Of studies included in the
meta-analysis, patient satisfaction could be assessed in only
one study [10] and showed no signiﬁcant diﬀerence between
groups. The school-based study [13] assessed patient satis-
factionin theintervention grouponly andfoundthat91% of
participantswouldusethetelemedicineservicesagain.Three4 International Journal of Pediatric Endocrinology
Table 2: HbA1c at baseline and at end of intervention of the 9 studies included in the meta-analysis.
Study HbA1c Inclusion
criteria
Mean (SD) HbA1c
baseline control (%)
Change in mean
HbA1c at followup
control (%)
Mean (SD) HbA1c
baseline TM (%)
Change in mean
HbA1c at followup
TM (%)
Cadario >7.0% ∗9.2 +0.2 ∗9.1 0
Chase 7.0%−13.0% 8.9 (1.1) −0.3 9.0 (1.2) −0.4
Gay ≥8.0% 9.2 (0.9) +0.1 9.3 (1.3) −0.2
Howe >8.5% 10.2 (1.4), ED 10.1
(1.2)
−0.5 10.0 (1.4) −0.5
Lawson >8.5% 9.7 (0.6) −0.1 10.0 (1.3) −0.6
Marrero None deﬁned 9.9 (1.6) +0.4 9.4 (1.9) +0.6
Nunn >8.0% 8.3 (1.0) +0.5 8.2 (1.1) +0.7
Panagiotopoulos ≥8.0% but <14.0% 9.6 (1.3) −0.5 9.7 (1.2) −0.9
Rami ≥8.0% †9.3 (8.3−11.6) +0.4 †9.1 (8.0−11.3) −0.1
ED: education.
∗No measure of variance reported.
†Median (range).
Table 3: Risk of Assessment of Bias of the 10 studies that met inclusion criteria.
Study Sequence
generation
Allocation
concealment
Blinding of
healthcare
providers
Blinding of data
collectors
Blinding of data
analyzers
Incomplete
outcome data
Selective
outcome
reporting
Cadario 2007 Unsure Unsure Unsure Unsure Unsure Inadequate Adequate
Chase 2003 Unsure Unsure Adequate Unsure Unsure Inadequate Adequate
Gay 2006 Adequate Unsure Unsure Unsure Unsure Inadequate Inadequate
Howe 2005 Adequate Unsure Unsure Unsure Unsure Inadequate Adequate
Izquierdo 2009 Unsure Unsure Unsure Unsure Unsure Inadequate Adequate
Lawson 2005 Adequate Adequate Adequate Adequate Adequate Adequate Adequate
Marrero 1995 Unsure Unsure Unsure Unsure Unsure Unsure Adequate
Nunn 2006 Adequate Unsure Inadequate Unsure Unsure Adequate Adequate
Panagiotopoulos
2003 Adequate Unsure Unsure Unsure Unsure Adequate Inadequate
Rami 2006 Unsure Unsure Unsure Unsure Unsure Adequate Adequate
Refer to the Cochrane Collaboration’s tool for assessing risk of bias [8] for the methods used to assess the risk of bias in studies.
studies reported diabetes-related quality of life (QoL) [13–
15], and none found signiﬁcant diﬀerences between groups.
Only two studies [9, 10] reported the cost of a clinic visit;
in one of these [10], the TM group did not attend the three-
monthvisitwithacostsavingsof$USD142.00.Indirectcosts
suchasmissedworkandschoolwereconsidered[10]b utnot
converted into dollar value nor incorporated in the overall
cost calculation.
4. Discussion
Ourresultsindicate that,despitea signiﬁcantincreasein new
studies, no robust eﬀect of TM on HbA1c was observed at
the end of the intervention. It remains possible that TM has
as m a l le ﬀect on HbA1c, but our data argue against a large
eﬀect. Our pooled analysis includes more than 100 subjects
per group giving us enough power to detect a diﬀerence
in HbA1c of 0.5%. Therefore, if there is an eﬀect of the
intervention on HbA1c, itis likely less than 0.5%. Ourresults
areconsistentwitharecentrandomizedcontroltrialexamin-
ing the eﬀect of telemedicine case management for diabetes
in an older population. This study involving 1,665 subjects
found an estimated 0.29% diﬀerence in HbA1c favoring
telemedicine at the end of 5 years between groups [20].
We do not believe that lack of eﬀect stems from selection
bias among included studies. We did not expand our deﬁni-
tion to include all uses of telemedicine, including web-based
education modules and teleconferences to conduct remote
clinic visits that did not necessarily include routine transmis-
sion of and feedback on blood glucose results, because that
would have resulted in a collection of heterogeneous inter-
ventions among which a combination and comparison of
outcomes would have been inappropriate in a meta-analysis.
Moreover, upon reviewing studies that were excluded by our
methods, we found that the results of those studies excluded
were similar to those that were included. Three randomized
controlled trials that were excluded from our review, because
they did not involve transmission of blood glucose data, also
found no eﬀect on glycemic control [21–23].International Journal of Pediatric Endocrinology 5
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Titles and abstracts screened (246)
Duplicates (188)
Excluded (189)
Studies selected for inclusion (10)
Excluded (47)
Wrong population, intervention, or study design (45)
Citations identiﬁed by electronic
database search (434)
Wrong population (39), intervention (61), study
design (7), or more than one exclusion (82)
Potentially relevant studies retrieved in full
text (57)
Satisﬁed eligibility criteria but no transmission
of data (2)
Either reviewer rated “include” or “unsure”
Figure 1: Process of selection of studies for inclusion.
Episodes of severe hypoglycemia and DKA were rare
and did not diﬀer between groups. Although data were
limited, there were no apparent diﬀerences in QoL or
patient satisfaction between groups. One study that used
TM to replace a clinic visit suggests a reduction in cost
with no increase in adverse eﬀects. Although we might have
expected adolescents to be more engaged in a telemedicine
intervention compared to younger children, a between-study
comparison found no diﬀerences in pooled estimates of
HbA1c at the end of the intervention between subgroups
based on age. However, it is possible that future, more
technology-based interventions may fare better.
We used the GRADE system because it provides explicit
andcomprehensivecriteriaforassessingthequalityofabody
of evidence. We recognize that based on this system, the
evidence in our study was determined to be low. This was,
in part, due to a necessary downgrade for the use of HbA1c
as an indirect measure. However, based on the results of
the DCCT [1, 2], HbA1c is regarded as a reliable surrogate
marker for long-term complications in T1DM. Therefore,
the quality of evidence is likely better than is reﬂected by the
GRADE system.
Despite disappointing initial results, many aspects of TM
interventions warrant further study. For example, between-
study subgroup analyses suggest a trend toward a greater
eﬀect of TM on HbA1c among participants with the highest
baseline HbA1c. Thus, determining whether TM could be
an important adjunct for patients with the poorest glycemic
control is worth further investigation in well designed,
adequately powered, long-term studies.
Although our study found no overall eﬀect on glycemic
control, it did not identify any detrimental eﬀects. Thus,
other factors to consider include whether TM may be
more eﬀective in subgroups of youth such as those living
remotely from the centres where care is provided. Reducing
the number of clinic visits, while maintaining glycemic
control, would be clinically desirable and potentially cost-
eﬀective. Thus, more studies are also needed to examine
the cost-utility of TM and to determine the eﬀects of TM
interventions that replace aspects of diabetes care. Such
studies should consider if TM would result in missed
opportunities for screening for complications and/or educa-
tion.
Finally, it will also be important to determine whether
the eﬀect of TM diﬀers depending on the expertise of the
individuals administering the TM, the frequency, and mode
of data transmission (SMS, email, mobile phone, smart
phone, personal digital assistant (PDA)) and whether the
interventioninvolvestheyouthand/ortheircaregivers,orthe
setting. One study that examined TM in the school setting
foundthattherewasadecreaseinthenumberofurgentvisits
to school nurses and calls to the diabetes centers. Successful
implementation of a school-based TM intervention depends
on the particular structure of the school system and may not
be feasible where there are no school nurses.
It was surprising that more of the recent studies did
not use more novel modes of data transmission such as
SMS or other telephone-based strategies. It is possible that
future studies examining the eﬀects of newer technologies
may show diﬀerent results compared to the studies currently
available for review. In addition to glycemic control and
complications, such studies should measure other patient-
important outcomes such as QoL, diabetes knowledge, and
patient satisfaction.International Journal of Pediatric Endocrinology 7
Study 
Rami 
Cadario 
Howe 
Panagiotopoulos 
Chase 
Marrero 
Gay
Lawson 
Nunn 
Total (95% CI)
Mean
9
9.1
9.5
8.8
8.6
10
9.1
9.4
8.9
SD
3.4
1.6
1.7
1.3
1.2
1.6
1.5
1.4
1.3
Total
18
14
26
25
30
52
36
23
63
287
Mean
9.7
9.4
9.7
9.1
8.6
10.3
9.3
9.6
8.8
SD
3.3
1.5
1.9
1.4
1.7
1.8
1.2
0.3
1.1
Total
18
12
21
25
33
54
35
23
60
281
3.7%
Weight
1.1%
4.9%
9.4%
10.2%
12.6%
13.3%
15.5%
29.3%
100%
Random, 95% CI
Control Mean difference Mean difference
IV, random, 95% CI
0 1 2
Favours TM Favours control
TM
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Figure 2: Meta-analysis of the eﬀect of TM. Weight assigned to each study was determined using the inverse variance (IV) method which
assigns weight based on the inverse of the variance of the eﬀect estimate (one over the square of the standard error). Studies with smaller
standard errors are given more weight than those with larger standard errors [19]. The size of the square representing the measure of eﬀect
is proportional to the percent weight assigned to each study on the forest plot.
5. Conclusions
In its recommendations about the structure of pediatric
diabetes care the International Society for Pediatric and
Adolescent Diabetes (ISPAD) recommends the use of TM
for patients living remotely from diabetes centres and
acknowledges that TM may result in improved diabetes
managementin allareas [5]. Ourpaperwill likely not change
current practice as diabetes care clinics will have to embrace
these novel forms of communication to mirror what patients
are using. Because of the small number and variable nature
of the available studies, we have tried to be careful not8 International Journal of Pediatric Endocrinology
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Figure 3: Meta-analysis of HbA1c at the end of the intervention with between-study comparison based on baseline HbA1c values. Weight
assigned to each study was determined using the inverse variance (IV) method which assigns weight based on the inverse of the variance of
the eﬀect estimate (one over the square of the standard error). Studies with smaller standard errors are given more weight than those with
larger standard errors [19]. The size of the square representing the measure of eﬀect is proportional to the percent weight assigned to each
study on the forest plot.
to overinterpret our results. However, given the potential
monetary and personnel costs involved in implementing TM
strategies, our paper does emphasize that TM should be well
studied before it is embraced and that care must be taken
to identify which subgroups of patients would maximally
beneﬁt and how we should deliver TM in the most time and
resource eﬃcient manner.
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